Teresa L Phillips

US Patent:

7425561, Sep 16, 2008

Filed:

Jul 18, 2006

Appl. No.:

11/458231

Inventors:

Anatoly A. Mazurov - Greensboro NC, US
Jozef Klucik - Rural Hall NC, US
Lan Miao - Advance NC, US
Angela S. Seamans - Jamestown NC, US
Teresa Youngpeter Phillips - Greensboro NC, US
Jeffrey Daniel Schmitt - Winston-Salem NC, US
Craig Harrison Miller - Winston-Salem NC, US

Assignee:

Targacept, Inc. - Winston-Salem NC

International Classification:

A61K 31/44
C07D 415/00
C07D 413/00
C07D 253/08

US Classification:

514299, 514305, 544133, 544137, 544112, 544183

Abstract:

The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a Calkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.

US Patent:

8084462, Dec 27, 2011

Filed:

Jun 4, 2010

Appl. No.:

12/793773

Inventors:

Anatoly A. Mazurov - Greensboro NC, US
Jozef Klucik - Marietta GA, US
Lan Miao - Advance NC, US
Angela S. Seamans - Jamestown NC, US
Teresa Youngpeter Phillips - Greensboro NC, US
Jeffrey Daniel Schmitt - Asheville NC, US
Craig Harrison Miller - Winston-Salem NC, US

Assignee:

Targacept, Inc. - Winston-Salem NC

International Classification:

A01N 43/42
A61K 31/44

US Classification:

514304

Abstract:

The present invention relates to the pharmaceutical compositions incorporating compounds capable of affecting nicotinic acetylcholinergic receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes (specifically, the α7 nAChR subtype). The present invention also relates to methods for treating a wide variety of conditions and disorders, particularly those associated with dysfunction of the central and autonomic nervous systems.

US Patent:

20040002513, Jan 1, 2004

Filed:

Feb 21, 2003

Appl. No.:

10/372642

Inventors:

Anatoly Mazurov - Greensboro NC, US
Jozef Klucik - Rural Hall NC, US
Lan Miao - Advance NC, US
Angela Seamans - Jamestown NC, US
Teresa Phillips - Greensboro NC, US
Jeffrey Schmitt - Winston-Salem NC, US
Craig Miller - Winston-Salem NC, US

International Classification:

C07D453/04
C07D453/02
A61K031/4745
A61K031/454
A61K031/407

US Classification:

514/305000, 514/412000, 514/323000, 546/135000, 546/199000, 548/453000

Abstract:

The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a Calkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the 7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.

US Patent:

20050255040, Nov 17, 2005

Filed:

Jun 20, 2005

Appl. No.:

11/157119

Inventors:

Anatoly Mazurov - Greensboro NC, US
Jozef Klucik - Rural Hall NC, US
Lan Maio - Advance NC, US
Angela Seamans - Jamestwon NC, US
Teresa Phillips - Greensboro NC, US
Jeffrey Schmitt - Winston-Salem NC, US
Craig Miller - Winston-Salem NC, US

International Classification:

A61K051/00
C07D453/04

US Classification:

424001110, 546135000, 546276700

Abstract:

The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a Calkyl. The substituent at the 3-position of the 1 -azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.